Wu Ching-Ying, Asano Yoshihide, Taniguchi Takashi, Sato Shinichi, Yu Hsin-Su
Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan.
Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
J Dermatol. 2016 Jan;43(1):63-6. doi: 10.1111/1346-8138.12986. Epub 2015 Jun 16.
Syndecan-1 is a member of the transmembrane heparan sulfate proteoglycan family, whose membrane-bound and soluble forms are involved in wound healing, inflammation and vascular biology. Because these physiological events are implicated in the pathogenesis of systemic sclerosis (SSc), we investigated the clinical association of serum syndecan-1 levels in this disease. Serum syndecan-1 levels were significantly higher in SSc patients, both in diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc), than in healthy individuals, while comparable between dcSSc and lcSSc groups. In late stage dcSSc patients (disease duration of >6 years), but not non-late stage dcSSc patients (≤6 years), serum syndecan-1 levels were significantly higher than in normal controls. More importantly, SSc patients with elevated serum syndecan-1 levels had higher prevalence of telangiectasia, elevated right ventricular systolic pressure and decreased diffuse capacity of the lung for carbon monoxide than those with normal levels. Therefore, soluble syndecan-1 may be related to the development of proliferative vasculopathy in SSc patients.
Syndecan-1是跨膜硫酸乙酰肝素蛋白聚糖家族的成员,其膜结合形式和可溶性形式参与伤口愈合、炎症和血管生物学过程。由于这些生理事件与系统性硬化症(SSc)的发病机制有关,我们研究了该病血清syndecan-1水平的临床相关性。SSc患者,包括弥漫性皮肤型SSc(dcSSc)和局限性皮肤型SSc(lcSSc),其血清syndecan-1水平显著高于健康个体,而dcSSc组和lcSSc组之间水平相当。在晚期dcSSc患者(病程>6年)中,而非非晚期dcSSc患者(≤6年),血清syndecan-1水平显著高于正常对照组。更重要的是,血清syndecan-1水平升高的SSc患者与正常水平患者相比,毛细血管扩张的患病率更高、右心室收缩压升高且肺一氧化碳弥散量降低。因此,可溶性syndecan-1可能与SSc患者增殖性血管病变的发展有关。